

METHYLATION DIFFERENCES IN THE MURINE P₁450 AND P₃450 GENES IN WILD-TYPE AND MUTANT HEPATOMA CELL CULTURE

THERESA C. PETERSON,* FRANK J. GONZALEZ† and DANIEL W. NEBERT‡

Laboratory of Developmental Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, U S A

(Received 19 June 1985; accepted 15 November 1985)

Abstract—The murine P₁450 and P₃450 genes and flanking regions contain 14 and 15 *Msp* I sites (C-C-G-G-), respectively, designated M1 through M14 or M15. These two genes from mouse Hepa-1 wild-type (wt) parent and three mutant cell lines were studied for methylation differences with use of the isoschizomers *Msp* I and *Hpa* II. The mutant lines included c1, having high constitutive P₁450 mRNA and believed to carry a mutation in the P₁450 structural gene, c2, having negligible levels of Ah receptor, and c4, having a defect in nuclear translocation of the inducer-receptor complex. The P₃450 gene was not expressed constitutively or after treatment of these four cell lines with the P₁450 inducer 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and, correspondingly, the P₃450 *Msp* I sites remained methylated. Treatment of all four cell lines with TCDD did not alter the P₁450 methylation pattern, nor was there any evidence of P₁450 gene amplification. Treatment of all four lines with 5-azacytidine caused demethylation of the P₁450 *Msp* I sites but did not change the usual P₁450 catalytic activity pattern found in each of the lines. The only detectable difference in the P₁450 gene among the four lines was hypomethylation of the M9 site in c1 that was not seen in wt, c2 and c4 cells. The M9 site is part of a 9-bp box (5'-C-C-G-G-G-A-C-A-T-3'), located near the beginning of exon 3. It is of interest that the same nine bases are found in intron 2 about 80 bp upstream from the 5' end of exon 3 in the homologous P₃450 gene.

The murine TCDD-inducible P450 gene family comprises two genes, P₁450 and P₃450 [1], which are controlled by the cytosolic Ah receptor [reviewed in Refs 2 and 3]. TCDD and other inducing foreign chemicals bind avidly to this receptor (apparent $K_d < 10^{-9}$). The inducer-receptor complex is translocated to the nucleus where P₁450 and P₃450 gene transcriptional activation occurs [reviewed in Ref. 4]. Developmental and tissue specificity in mouse P₁450 and P₃450 gene expression has also been determined [5].

The mouse hepatoma Hepa-1 cell line has inducible P₁450 expression but no constitutive or inducible P₃450 expression [6]. The P₁450 induction process has been studied extensively by somatic cell hybridization [reviewed in Ref. 7]. These studies with benzo[*a*]pyrene-resistant mutant clones have shown that all recessive mutants belong to three complementation groups—A, B and C—indicating involvement of at least three genes in the P₁450

induction process [8]. The c1 variant (Group A, subgroup IV) exhibits markedly elevated constitutive P₁450 mRNA [9] and is believed to carry a mutation in the P₁450 structural gene [10]. Groups B and C are regulatory mutants. The c2 variant (Group B) has Ah receptor levels that are less than 5% of those in wt cells [11]. The c4 variant (Group C) has a normal cytosolic Ah receptor concentration but impaired nuclear translocation of the inducer-receptor complex [11].

Changes in DNA methylation patterns may be a cause, or the result, of changes in eukaryotic gene expression [12-14]. In eukaryotes, the sites of methylation are almost invariably the C-5 position of cytosine and, in animals, CpG is the usual sequence which contains 5-methylcytosine. The isoschizomers *Hpa* II and *Msp* I cleave the sequence C-C-G-G, methylation of the internal C residue renders this sequence resistant to *Hpa* II but not to *Msp* I. With use of these isoschizomers and the Southern blot technique, methylation at those CpG sites embedded in a C-C-G-G sequence can be assessed [15, 16].

In this report we examine DNA methylation patterns of the P₁450 and P₃450 genes among control and TCDD-treated wt cells at the c1, c2 and c4 variant cells. Differences in methylation pattern between the c1 variant and wt cells might contribute to the mechanism by which high constitutive P₁450 mRNA is expressed in the c1 variant cell line. The c2 and c4 regulatory mutants were used as controls in which no differences in methylation patterns between these variants and wt cells were expected.

* Present address: Clinical Research Centre, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7.

‡ Present address: Laboratory of Molecular Carcinogenesis, Building 37, Room 3E-24, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

‡ Corresponding author: Dr Daniel W. Nebert, Building 10, Room 6C-101, National Institutes of Health, Bethesda, MD 20892.

§ Abbreviations: TCDD, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, wt, wild-type, MEM, Eagle's Minimum Essential Medium, bp, base-pairs, and kb, kilobases.

EXPERIMENTAL PROCEDURES

Materials

All tissue culture solutions and fetal calf serum were purchased from GIBCO (Grand Island, NY), tissue culture plastic ware was bought from Falcon Plastics (Oxnard, CA), nitrocellulose paper was obtained from the Millipore corp. (Bedford, MA), restriction endonucleases were purchased from BRL (Rockville, MD), 5-azacytidine was obtained from the Sigma Chemical Co. (St. Louis, MO); and [γ - 32 P]ATP was bought from Amersham Radiochemicals (Cambridge, MA). TCDD was a gift from the Dow Chemical Co. (Midland, MI)

Cell cultures

The origin and development of the Hepa-1 wild-type line [17] and the c1, c2 and c4 mutants [8, 18, 19] have been described. Cultures were grown as monolayers at 37° in 95% air and 5% CO₂ in α -MEM medium supplemented with 10% fetal calf serum, penicillin (40 units/ml), streptomycin (40 μ g/ml) and Mycostatin (25 μ g/ml). Cells were plated at a density of 10⁶ per 125-cm² T-flask and treated with TCDD (or control medium alone) during the second half of the logarithmic growth phase. Unless otherwise indicated, the TCDD concentration was 10 nM. In some experiments, the cultures were exposed to 5-

azacytidine (3 μ M). For experiments lasting more than 24 hr, the medium was replaced each day. All experiments were repeated two to four times to ensure reproducibility.

Southern hybridizations

DNA was isolated by the method of Blin and Stafford [20]. Restriction endonucleases were used according to the protocol of the vendor. Control DNA fragments having known sites were always included to ensure complete cutting by the restriction enzymes in each experiment. The DNA fragments were separated by electrophoresis on agarose gels (0.7 to 1.4%), along with λ phage DNA molecular weight standards (BRL, Rockville, MD). The fragments were blotted onto nitrocellulose membranes [21] and hybridized to nick-translated 32 P-labeled probes [22] for 36 hr as described previously [23]. The filters were then washed three times with 3X SSC (1X SSC = 150 mM NaCl and 15 mM sodium citrate) plus 0.5% sodium dodecyl sulfate for 1 hr at 68°, followed by one wash with 1X SSC at room temperature. Filters were exposed to Kodak RP-5 X-ray film at -70° for 2 days to 2 weeks with the use of intensifier screens (Lightning Plus, Dupont, Wilmington, DE). The probes included P₁450 and P₃450 full-length cDNA inserts, pP₁450FL and pP₃450FL, respectively [23], a 0.40-kb segment




Fig 1 Exon-intron patterns of the P₁450 and P₃450 genes and flanking regions. The seven exons of each gene are shown as closed boxes. A 0.5-kb stretch of 96% similarity between the two homologous genes in exon 2 [24] is shown as a striped area. Because of the strongly conserved sequence of the two cDNAs in the exon 2 region, the pP₃450FL probe cross-hybridizes with the P₁450 1.18 kb fragment. *Msp*I sites (M1 through M14 or M15) on each gene are denoted by vertical lines. Fragments theoretically detectable by either cDNA or genomic probes are illustrated, although fragments of less than 0.4 kb did not consistently transfer to the nitrocellulose membranes.




Fig 2 (A) Southern blot hybridization of the four cell lines' probed with DNA digested with each of three restriction enzymes and pP₁450FL




Fig 2 (B) The positions of the pP₁StuI and pP₁A genomic probes and the fragments detected by pP₁450FL. The 14 *Msp* I sites and seven exons of the P₁450 gene are depicted as in Fig 1. The numbers at the right of each fragment are given in kb.




Fig. 2 (C) Hybridization analysis of wt, c1, c2 and c4 DNA digested with *Hpa* II and *Msp* I and probed with pP₁StuI. The numbers at the margins of each Southern plot in panels A and C denote the fragment length in kb

(pP₁A) covering 380 bp upstream from the P₁450 cap site and a portion of the first exon [1], and a 1.2-kb *Stu* I fragment (pP₁StuI) covering portions of the first intron and second exon of P₁450 [1]

RESULTS AND DISCUSSION

P₁450 genomic DNA studied with a single restriction endonuclease digestion

Sequence analysis of the mouse P₁450 gene and flanking regions [1] revealed 14 *Msp* I sites (Fig. 1, top), these sites are referred to as M1 through M14. The P₃-450 gene [1] has 15 *Msp* I sites (M1 through M15) (Fig. 1, bottom). When the pP₁450FL probe was used (Fig. 2A), no differences in the major *Msp* I fragments of P₁450 (3.2, 2.4 and 1.18 kb, [0.56 and 0.42 kb data not shown]) among wt and the c1, c2 and c4 variants were detected. The 2.4-kb band is very weak because it hybridizes only to the 87 bases of exon 1 of P₁450 [1].

Eco RI-digested DNA probed with pP₁450FL yielded the same pattern in all four cell lines (Fig. 2A), with major bands of 15 and 3.5 kb (minor bands of 10.5 and 2.9 kb represent cross-hybridization with the P₃450 gene). The results with *Msp* I and *Eco* RI (and *Bam* HI data, not included) thus indicate that

any differences in the *Hpa* II pattern among the four cell lines would not be due to genomic rearrangement or translocation but rather to a methylation polymorphism.

Hpa II-digested DNA probed with pP₁450FL (Fig. 2A) gave identical patterns for wt and the two regulatory mutant clones c2 and c4, with fragment sizes of 8.1, 7.5 and 2.4 kb. It had been anticipated that the c2 and c4 regulatory mutants would exhibit patterns identical to the pattern of wt cells and thus could be used as control cell lines. As compared with wt, c2 and c4 (Figs. 2A and 2B), clone c1 exhibited a different pattern (6.2, 3.2, 2.4 and 1.18 kb). This pattern suggests a loss of methyl groups at sites M9, M13 and M14.

The results in Fig. 2A suggest that sites M5, M6 and M7 (and/or M8) are hypomethylated in all four lines. As expected, *Hpa* II- and *Msp* I-digested DNA from all four lines probed with pP₁StuI gave identical fragments of 2.4 kb (Fig. 2C).

When *Hpa* II- and *Msp* I-digested DNA was probed with the 5' genomic probe pP₁A, no fragments of sufficient length were found to be transferred to the nitrocellulose membranes. These data indicate that one or more of the sites M1 through M5 is(are) hypomethylated in all four lines tested. As is commonly the case for any gene flanking regions in which




Fig. 3 (A) Southern blot hybridization of wt and c1 DNA digested with *Eco* RI and either *Hpa* II or *Msp* I and probed with pP₁450FL (B) The *Hpa* II/*Eco* RI fragments (kb) detected with the pP₁450FL probe. The 14 *Msp* I sites and seven exons of the P₁450 gene are illustrated as in Figs. 1 and 2.

Msp I sites are close to one another [13], DNA methylation of the P₁450 sites M1 through M5 cannot be adequately assessed due to limitations in the Southern blotting method.

P₁450 genomic DNA studied with double restriction endonuclease digestions

An *Eco* RI site at the beginning of exon 5 [1] afforded us the opportunity to study in more detail the c1 mutant's methylation differences shown in Fig. 2. Double digestions of wt and c1 DNA with *Eco* RI and *Hpa* II gave similar patterns when probed with pP₁450FL, except for the 1.56-kb fragment pres-

ent in wt but not c1 cells (Fig. 3A). This finding strongly suggests a loss of cytosine methylation at site M9 in the c1 variant (Fig. 3B).

P₃450 genomic DNA studied with *Msp* I and *Hpa* II

As predicted from Fig. 1, *Msp* I digestion of wt and c1 DNA probed with pP₃450FL yielded fragments of 1.8, 1.64 and 1.3 kb (Fig. 4), and in other gels the smaller fragments (1.1 and 0.6) were found (data not shown). *Hpa* II-digested DNA probed with pP₃450FL gave fragments of 10 to 14 kb in wt and c1 cells (Fig. 4), indicating that no significant hypomethylation of the P₃450 gene had taken place. The




Fig. 4 Southern blot hybridization of wt and c1 DNA digested with *Hpa* II or *Msp* I and probed with pP₃450FL. See Fig. 1 for P₃450 fragments that are theoretically detectable by this experiment

Southern blot patterns of *Msp* I- and *Hpa* II-digested DNA probed with pP₃450FL from c2 and c4 were similar to the corresponding patterns of wt and c1 cells (results not illustrated). The data in Fig. 4 are thus consistent with the observation that the Hepa-1 P₃450 gene is neither expressed constitutively nor inducible by TCDD [6]. The underlying reasons for this interesting lack of P₃450 gene expression in Hepa-1 cultures remain to be elucidated.

No evidence for gene amplification or change in DNA methylation caused by the inducer

TCDD is known to induce the wt P₁450 mRNA, to have no effect on the already elevated P₁450 mRNA in c1, and not to induce P₁450 mRNA in the c2 and c4 lines [9]. TCDD exposure (1 and 10 nM) of all four cell lines for times ranging from 16 hr to 1 week did not alter the methylation status of either the P₁450 or P₃450 gene. Moreover, when




Fig. 5 Southern blot hybridization of 5-azacytidine-treated wt, c1, c2 and c4 DNA digested with *Hpa* II or *Msp* I and probed with pP₁450FL. See Fig. 1 for P₁450 fragments that are theoretically detectable by this experiment

Southern blots of the wt line were compared with Southern blots of the three mutant lines, there was no evidence for P₁450 or P₃450 gene amplification as the result of such prolonged high doses of TCDD (data not shown).

5-Azacytidine treatment

Continuous exposure of all four cell lines to 5-azacytidine (3 μ M) for 24 hr or 48 hr caused extensive hypomethylation in both genes (Fig. 5) but did not change the previously characterized P₁450 or P₃450 catalytic activity status in wt or the three mutant lines. These findings suggest that hypomethylation of the M9 site *per se* in wt cells was insufficient to mimic the situation in the c1 variant where high constitutive P₁450 mRNA levels were observed. The results with 5-azacytidine also show that inducible genes do not necessarily respond to additional hypomethylation outside the control region. It would be

MOUSE P₁-450 GENE, PORTION OF INTRON 2 AND EXON 3

```

      3840          3860          3880          3900          3920
CTTCATGGTA GAAAAAGTT AAAGAACTCA TCAATAACT AACAGTGTCA GGCTCTGTGC CTCAGGGTC ACTTGAGTTG GGTATTCAT TCTTTAAGT

      3940          3960          3980          4000          4020
AGAAAGAGAC TTGAGAGAC AAGGGGAAAA TGGGACAGCA GCTCAACCAT GACATCTCTT TAACAGTGAG GGGCCAGGOC TAGATGGATG GTTAGGTCG

      4040          4060          4080          4100          4120
GGATATTTCT CAOCTTGGTC TCCTTTGTCTCCAG GGCCACATCCGGGACATCACAGACAGCCTATTGAGCATTGTGACAGGACGAAGCTGGAAGAGAATGCCAA
      G H I R D I T D S L I E H C Q D R K L D E N A N

      4160          4180          4200          4220          4240
TGTCAGCTGTGAGATGATAAGGTCATCAAGATTGTTTGGACCTCTTTGGAGCTG GTACGTGT ACTTTGGTGT ATCATTCTCTG TGCTCAGGTG CCGCTAGTTG
V Q L S D D K V I T I V L D L F G A

```

MOUSE P₃-450 GENE, PORTION OF INTRON 2 AND EXON 3:

```

      2280          2300          2320          2340          2360
AGGCTACGTA AGCTCAGCT TCGTGTCACT TTTCTTCCCT GTGTTCAACC TAOCCTCTTC TCCTCTGAAA CCGTAGCCCT GGGTTATG GAAAGAAGGG

      2380          2400          2420          2440          2460
TCAGGGGTAC ATGAAATGAC TAACTCTAT TTAGGGCTGA TGCTAGTTCA AAAATCTGAG CTCTAGCCCA GGGCTGGAG ACCAAGGCAG TTCCAGGCC

      2480          2500          2520          2540          2560
CCGGGACAT ATCAAAATGG ATGGTAAGG TTGGGCATT GGCCCTGGAA GTGCCAAAGT TAOCCTGAAC TTATGTCTCTAG AACAGTATCAAGACA
      N S I Q D

      2580          2600          2620          2640          2660
TCACAAGTGCCCTGTTCAAGCACAGGAGAACTACAAAGACAATGGGGTCTCATCCCGAGGAGAAAGATTGTCAACATTGTCAATGACATCTTTGGAGCTG GTAGGAGC
I T S A L F K H S E N Y K D N G G L I P E E K I V N I V N D I F G A

      2680          2700          2720          2740          2760
CAOCTTTCTG CCGCTCAGTC CACCAATTGC TATTCACCA TATACAACCT CATCAACCAC ATCAGGTGAC ACACAACAGA CTCTGCGCTC AAGATCAAGG

```

Fig. 6 Portions of introns 2 and 3 and exon 3 of the P₁450 and P₃450 genes. The exon and its corresponding encoded amino acids are illustrated without spacing between nucleotides, intron DNA nucleotides are placed in groups of ten. Numbering of the nucleotides in either gene corresponds to +1 of the first exon, as determined by primer extension and S1 mapping [1]. The *Msp* I sites M9 of P₁450 and M8 of P₃450 (C-C-G-G) are contained within the conserved 9-bp boxes, denoted as *closed boxes*.

interesting to examine in greater detail the methylation pattern of the 5'-flanking region of P₃450 in these cell lines.

Speculation about Msp I site M9 in the P₁450 gene

In conclusion, the major methylation difference in the c1 mutant that is not seen in the wt or the regulatory mutants c2 and c4 involves hypomethylation of the M9 site, located near the 5' end of exon 3 of the P₁450 gene (Fig. 6). The reason for the hypomethylation difference in the P₁450 M9 site of the c1 variant is not known. Despite the fact that 5-azacytidine treatment failed to convert the wt phenotype to the c1 phenotype, it is tempting to speculate that M9 represents a potential control site within the gene. This control site may play a role in the c1 variant's expression of high constitutive P₁-450 mRNA levels.

The M9 site of the P₁450 gene is part of a 9-bp box (5'-C-C-G-G-G-A-C-A-T-3') identical to the M8 site of P₃450, located about 80 bp upstream from the beginning of exon 3 (Fig. 6). The third exon of P₁450 contains 127 bp, whereas the third exon of P₃450 contains 118 bp. The P₁450 and P₃450 genes most likely arose via duplication of an ancestral gene at least 65 million years ago [1, 24]. Following this gene duplication, it is possible that P₃450 underwent an internal duplication or an insertion of about 80 bp at the 5' end of exon 3. The more upstream of the two

9-bp boxes in P₃450 may have been retained as the important regulatory site, while the other 9-bp box was lost because there was no longer any evolutionary pressure to retain this secondary site. The regions surrounding the single conserved 9-bp box then diverged at the normal rate for intron DNA having no apparent function [1], and the resultant P₃-450 exon 3 has nine fewer bases. Consistent with this scenario is the presence of the conserved 9-bp box in exon 3 of the rat P450c gene which corresponds to mouse P₁450 [25], and the presence of a homologous region (5'-C-C-G-G-G-A-C-A-C-A-T-3') 172 bases upstream from the start of exon 3 in the rat P450d gene which corresponds to mouse P₃450 [26]. Furthermore, the 9-bp box is completely conserved at the beginning of exon 3 in the human P₁450 gene [27].

The P₁450 exon 3 has diverged 3% between mouse and rat [1, 25] and 11–13% between either rodent and human [27]. The P₃450 intron 2 has diverged 21% between mouse and rat [1, 26]. The fact that these two 9-bp boxes have been highly conserved, despite one existing in an exon and the other within a more rapidly diverging intron, provides further evidence for speculation that these 9-bp boxes might possess an important function. Further studies on P₁450 and P₃450 gene transcriptional activation will be necessary to test the potential function of this conserved 9-bp box as a control site within the gene.

Acknowledgements—We thank Oliver Hankinson for sharing these cell lines with us. We also thank Kathleen Dixon and Ed Max for critical reading of this manuscript. The expert secretarial assistance of Ingrid E. Jordan is greatly appreciated.

REFERENCES

- 1 F J Gonzalez, S Kimura and D W Nebert, *J biol Chem* **260**, 5040 (1985)
- 2 H. J. Eisen, R. R. Hannah, C. Legraverend, A. B. Okey and D. W. Nebert, *Biochemical Actions of Hormones* (Ed. G. Litwack), Vol. X, p. 227. Academic Press, New York (1983)
- 3 D. W. Nebert and F. J. Gonzalez, *Trends pharmac Sci* **6**, 160 (1985)
- 4 D. W. Nebert, S. Kimura and F. J. Gonzalez, *Molecular Biology of Development* (Eds. E. H. Davidson and R. A. Firtel), p. 309. Alan R. Liss, New York (1984)
- 5 N. Tuteja, F. J. Gonzalez and D. W. Nebert, *Dev Biol* **112**, 177 (1985)
- 6 A. K. Jaiswal, D. W. Nebert and H. J. Eisen, *Biochem Pharmac* **34**, 2721 (1985)
- 7 D. W. Nebert, H. J. Eisen and O. Hankinson, *Biochem Pharmac* **33**, 917 (1984)
- 8 O. Hankinson, *Somat Cell Genet* **9**, 497 (1983)
- 9 O. Hankinson, R. D. Andersen, B. Birren, F. Sander, M. Negishi and D. W. Nebert, *J biol Chem* **260**, 1790 (1985)
- 10 D. F. Montisano and O. Hankinson, *Molec cell Biol* **5**, 698 (1985)
- 11 C. Legraverend, R. R. Hannah, H. J. Eisen, I. S. Owens, D. W. Nebert and O. Hankinson, *J biol Chem* **257**, 6402 (1982)
- 12 A. P. Bird, *Nature, Lond* **307**, 503 (1984)
- 13 E. E. Max, *Nature, Lond* **310**, 100 (1984)
- 14 A. D. Riggs and P. A. Jones, *Adv Cancer Res* **40**, 1 (1983)
- 15 C. Waalwijk and R. A. Flavell, *Nucleic Acids Res* **5**, 3231 (1978)
- 16 M. McClelland, *Nucleic Acids Res* **11**, r169 (1983)
- 17 H. P. Bernhard, G. J. Darlington and F. H. Ruddle, *Devl Biol* **35**, 83 (1973)
- 18 O. Hankinson, *Proc natn Acad Sci U S A* **76**, 373 (1979)
- 19 O. Hankinson, *Somat Cell Genet* **7**, 373 (1981)
- 20 N. Blin and D. W. Stafford, *Nucleic Acids Res* **3**, 2303 (1976)
- 21 E. M. Southern, *J molec Biol* **98**, 503 (1975)
- 22 S. Y. Tsai, D. R. Roop, M.-J. Tsai, J. P. Stein, A. R. Means and B. W. O'Malley, *Biochemistry* **17**, 5773 (1978)
- 23 F. J. Gonzalez, P. I. Mackenzie, S. Kimura and D. W. Nebert, *Gene* **29**, 281 (1984)
- 24 S. Kimura, F. J. Gonzalez and D. W. Nebert, *J biol Chem* **259**, 10705 (1984)
- 25 K. Sogawa, O. Gotoh, K. Kawajiri and Y. Fujii-Kuriyama, *Proc natn Acad Sci U S A* **81**, 5066 (1984)
- 26 K. Sogawa, O. Gotoh, K. Kawajiri, T. Harada and Y. Fujii-Kuriyama, *J biol Chem* **260**, 5026 (1985)
- 27 A. K. Jaiswal, F. J. Gonzalez and D. W. Nebert, *Nucleic Acids Res* **13**, 4503 (1985)